Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 16, 2023 08:00 ET | Source: Frontera Therapeutics

Frontera Therapeutics Doses First Patient in a Trial of FT-002 Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa

BEDFORD, Mass. and SHANGHAI, China, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy...
February 02, 2023 09:00 ET | Source: Frontera Therapeutics

Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy for the Treatment of Wet AMD

BEDFORD, Mass. and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy...
January 06, 2023 09:00 ET | Source: Frontera Therapeutics

Frontera Therapeutics Doses First Patient in Phase 1 Clinical Trial for Gene Therapy FT-001 for the Treatment of Leber Congenital Amaurosis-2

BEDFORD, Mass., and SHANGHAI, China, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy...
September 21, 2022 08:00 ET | Source: Frontera Therapeutics

Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001

BEDFORD, Mass. and SHANGHAI, China, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy...
July 19, 2022 08:00 ET | Source: Frontera Therapeutics

Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities

FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease leading to severe visual impairment that may...